ExoFem Clinic Track — Professional Formats with a Documentation Chain

The problem this playbook solves: women's health clinic categories have no documented professional formats — clinics need gentle, professional-use products with a documentation chain, not another herbal backbar.

01 · The problem

Women's health clinics and sensitive-care practices need professional formats for comfort-stage programs — and the shelf gives them either herbal backbar with no files or medical products with the wrong register. The ExoFem clinic track fills the professional layer behind the established C-end line: same rose-EV baseline, professional-use labelling, staged protocols.

02 · Scientific rationale

The clinic track deliberately follows C-end maturity: retail formats establish the documentation chain and consumer trust first; professional formats then inherit a known baseline. Guardrails (labelling, protocols, staff briefings) inherit the C-end line's wording discipline — in sensitive categories, a claim failure is unrecoverable.

03 · Program documentation

Clinic-format protocols live in internal professional-use files; the C-end documentation (COA chain, characterization baseline) carries over unchanged.

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [5].

Fig. 1 — The staged track: consumer trust first, then clinic formats.

06 · Regulatory pathway: EU & US first

EU: Regulation (EC) No 1223/2009 — CPNP notification, Responsible Person, PIF/CPSR. US: MoCRA (2022) registration and listing; INCI labelling (41316). Appearance-level claims only per EU Reg. 655/2013 and US advertising standards. China market entry maps to the CSAR track later, as an additional market. Clinic track: professional-use wording; no health claims in any market.

07 · Expected outcomes

• Staged credibility: consumer-facing documentation builds trust first; clinic formats inherit it.
• Soft-care discipline carried into professional channels unchanged.
• Protocol cards make the program run by clinic staff, not just the founder.

No claims are made beyond the destination-market framing — authority comes from documentation and batch measurement.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label runs through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. TONGNIAN. Rose-derived plant EV platform documentation (internal).
3. Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
4. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17) — TONGNIAN, drafting organization.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).